Disordered proliferative endometrium is a noncancerous (benign) change in the lining of the uterus, which is called the endometrium. It develops when the lining is exposed to estrogen over a long period without enough progesterone to balance it. Under the microscope, the glands of the lining look irregular and unevenly distributed instead of neat and evenly spaced.
This describes a pattern rather than a disease with a single cause. It is not cancer, it is not precancerous, and on its own it does not raise the risk of endometrial cancer. What it does tell you is that your hormone balance has been tilted toward estrogen for some time, and identifying why is the useful part of the diagnosis.
Your report may use other names for the same pattern, including anovulatory endometrium or persistent proliferative endometrium. This article will help you understand what this term means on your pathology report and why it matters for your care.
What causes disordered proliferative endometrium?
Two hormones control the lining of the uterus. Estrogen makes it grow. Progesterone matures it and prepares it to shed. Progesterone is produced only after an egg is released, so any situation in which ovulation does not happen leaves the lining exposed to estrogen alone. Pathologists call this unopposed estrogen.
Over months, unopposed estrogen makes the glands grow unevenly. Some become dilated or branched, and they no longer line up regularly through the lining. That uneven pattern is what the phrase describes. Situations that produce it include:
- Cycles without ovulation — The most common reason. This is normal at either end of reproductive life, in the years after periods begin and in the years leading up to menopause.
- Polycystic ovary syndrome — A hormonal condition in which ovulation happens irregularly or not at all.
- Excess body weight — Fat tissue converts other hormones into estrogen, so higher body weight means more estrogen reaching the lining.
- Estrogen without progesterone — Hormone therapy containing estrogen alone, taken by someone who still has a uterus.
- Estrogen-producing ovarian tumors — Uncommon, but a thecoma or a granulosa cell tumor can produce enough estrogen to cause this pattern.
What are the symptoms?
The usual reason for the biopsy is abnormal bleeding, and that bleeding is a direct result of the same hormone imbalance. A lining that keeps growing without progesterone eventually outgrows its blood supply and sheds in a patchy, unpredictable way.
- Irregular periods — Cycles that are unpredictable in timing, or long gaps followed by heavy bleeding.
- Heavy or prolonged bleeding — Periods heavier or longer than usual for you.
- Bleeding between periods — Spotting or bleeding when a period is not expected.
- Bleeding after menopause — Any bleeding after menopause should be assessed promptly, whatever the eventual cause.
Some people have no symptoms, and the change is found in tissue removed for another reason.
How is the diagnosis made?
A pathologist diagnoses it by examining a sample of the lining under a microscope. The sample usually comes from an endometrial biopsy, a brief clinic procedure using a thin flexible tube, or from a dilation and curettage. It may also come from a uterus removed at surgery.
An ultrasound may show a thickened lining beforehand, but a scan cannot distinguish this pattern from endometrial hyperplasia or from other causes of thickening. Only tissue examination can do that.
The pathologist’s task is to place the sample along a range, from a normal lining at one end to hyperplasia and precancerous change at the other. Disordered proliferative endometrium sits close to the normal end.
What does disordered proliferative endometrium look like under the microscope?
Disordered proliferative endometrium is a lining of the uterus in which the glands are irregular in shape and unevenly distributed, but not crowded together. Under the microscope, the pathologist looks for the following features.
- Irregular gland shapes — The endometrial glands vary in size. Some are dilated, some are branched, and some are angular rather than round.
- Uneven spacing — The glands are scattered unevenly through the supporting tissue rather than distributed regularly. Areas of normal-looking lining sit next to affected areas.
- Normal amounts of supporting tissue — There is still plenty of tissue between the glands. This is what separates this change from hyperplasia, where the glands become crowded together.
- Actively growing cells — The lining cells show signs of active growth, consistent with continuing estrogen stimulation and with no progesterone effect.
- Normal-looking cells — The cells lining the glands look ordinary. There is no atypia, which is the term for cells that look abnormal.
- Breakdown and bleeding — Areas where the lining is shedding are common and explain the bleeding that prompted the biopsy.
How is this different from other endometrial diagnoses?
Disordered proliferative endometrium sits within a range of diagnoses that reflect increasing degrees of the same hormonal imbalance. Your report may mention any of the following.
- Proliferative endometrium — A normal lining in the first half of the cycle, with evenly spaced, regular glands. Proliferative endometrium is a normal finding, not a diagnosis of a problem.
- Disordered proliferative endometrium — Irregular, unevenly spaced glands without crowding. Not precancerous.
- Hyperplasia without atypia — The glands become genuinely crowded, with less tissue between them. Endometrial hyperplasia without atypia carries a small risk of progressing to cancer, under 5 in 100 over 20 years.
- Atypical hyperplasia — Crowded glands together with abnormal-looking cells. Atypical endometrial hyperplasia, also called endometrioid intraepithelial neoplasia, is precancerous.
These categories describe points along a continuum rather than sharply separated conditions. The step from disordered proliferative endometrium to hyperplasia without atypia is a judgment about how crowded the glands have become. Pathologists do not always place that line in the same spot. Some pathologists use this term frequently and others rarely. If you have had two biopsies reported differently, this is often the explanation rather than a change in your condition.
Does disordered proliferative endometrium increase the risk of cancer?
Not by itself. This pattern is not precancerous and is not a step on the path to cancer in the way that atypical hyperplasia is. Studies following patients with this diagnosis have not found an increased rate of endometrial cancer attributable to the change itself.
What matters is the cause. The unopposed estrogen that produced this pattern is itself a risk factor for endometrial hyperplasia and, over longer periods, for endometrial cancer. Treating the imbalance is worthwhile, not because the change on the slide is dangerous, but because the hormonal state that caused it can go on to cause something that is.
The situation deserves more attention after menopause. By then, the ovaries have stopped producing estrogen, so a lining showing continued estrogen stimulation means the estrogen is coming from somewhere else. Excess body weight and hormone therapy are the usual explanations, and an estrogen-producing ovarian tumor is an uncommon one. If you have gone through menopause and your report describes this pattern, ask your doctor where the estrogen is likely coming from.
How is disordered proliferative endometrium treated?
Treatment targets the hormone imbalance and the bleeding, rather than the microscopic change. Whether treatment is needed at all depends on your symptoms and your situation. Options your doctor may discuss include:
- Progestin treatment — Progestin is a synthetic form of progesterone. It can be given as tablets or through a hormonal IUD, and it counteracts the effect of estrogen on the lining. It usually controls the bleeding as well.
- Combined hormonal contraception — A useful option for someone who is not ovulating regularly and also wants contraception.
- Addressing the underlying cause — Reviewing estrogen-only hormone therapy, managing polycystic ovary syndrome, or weight reduction where relevant.
- Observation — Reasonable when there are no symptoms and no ongoing source of unopposed estrogen. This is a decision to make with your doctor, not an automatic option.
- Further investigation — If bleeding continues despite treatment, a repeat biopsy or a hysteroscopy may be arranged to be sure nothing was missed on the first sample.
What other findings may be described in the report?
Your report may describe other features of the lining alongside this one.
- Endometrial polyp — A benign overgrowth of the lining, and a common cause of abnormal bleeding in its own right.
- Breakdown and bleeding — Changes in a lining that is shedding, often the direct explanation for the symptoms.
- Chronic inflammation — If plasma cells are present, the report may also diagnose chronic endometritis.
- Metaplasia — Areas where the lining cells have taken on a different but still normal appearance. This is common and is not precancerous.
- Sample adequacy — The report may note that the sample was scant or fragmented. This does not mean the diagnosis is wrong, but a repeat sample may be needed to be confident nothing was missed.
Questions to ask your doctor
- What do you think is causing the hormone imbalance in my case?
- Does this finding explain my bleeding?
- Is this a precancerous change?
- Do I need treatment, or is observation reasonable for me?
- Would progestin tablets or a hormonal IUD suit me better?
- Should I stop or change my hormone therapy?
- I have gone through menopause. Where might the estrogen be coming from?
- Was the sample adequate, or should it be repeated?
- Was an endometrial polyp or any other finding reported?
- Will I need a repeat biopsy, and if so, when?
- Could this progress to endometrial hyperplasia?
- What symptoms should prompt me to contact you?
Related articles on MyPathologyReport.com